糖心vlog

[Skip to Navigation]
Sign In

October 2024 - April 2016

Decade

Year

Issue

May 2016, Vol 1, No. 2, Pages 115-239

In This Issue of JAMA Cardiology

Highlights

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):115. doi:10.1001/jamacardio.2015.0008
Original Investigation

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
free access has audio
JAMA Cardiol. 2016;1(2):126-135. doi:10.1001/jamacardio.2016.0103

This secondary analysis of the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) assesses the association of sitagliptin use with hospitalization for heart failure and related outcomes among patients with type 2 diabetes mellitus and atherosclerotic vascular disease.

Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):136-145. doi:10.1001/jamacardio.2016.0096

This secondary analysis of the JUPITER randomized clinical trial investigates the association of lipoprotein subclasses and size and insulin resistance with incident type 2 diabetes mellitus in individuals randomized to a high-intensity statin.

Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):147-155. doi:10.1001/jamacardio.2016.0001

This observational study uses the Acute Coronary Treatment and Intervention Network Registry鈥揋et With the Guidelines (ACTION Registry鈥揋WTG) linked with Medicare Part D prescription fill data to examine the association between follow-up time and adherence to medications prescribed after acute myocardial infarction in Medicare-insured patients.

Atherosclerotic Burden and Heart Failure After Myocardial Infarction

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):156-162. doi:10.1001/jamacardio.2016.0074

This population-based study examines the association between the extent of coronary artery disease present after myocardial infarction and the development of heart failure.

Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial

Abstract Full Text
open access
JAMA Cardiol. 2016;1(2):163-171. doi:10.1001/jamacardio.2016.0008

This randomized clinical trial evaluates the effect of gene transfer through intracoronary administration of adenovirus 5 encoding adenylyl cyclase 6 on left ventricular function in patients with heart failure.

Outcomes in a Warfarin-Treated Population With Atrial Fibrillation

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):172-180. doi:10.1001/jamacardio.2016.0199

This cohort study evaluates the safety and efficacy of warfarin, with and without concomitant aspirin, in prophylaxis of stroke associated with atrial fibrillation.

Time Course of Subsequent Shocks After Initial Implantable Cardioverter-Defibrillator Discharge and Implications for Driving Restrictions

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):181-188. doi:10.1001/jamacardio.2015.0386

This cohort study investigates the time course of subsequent shocks after an initial implantable cardioverter-defibrillator (ICD) discharge in a national population of implant recipients.

Resuscitation Practices Associated With Survival After In-Hospital Cardiac Arrest: A Nationwide Survey

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):189-197. doi:10.1001/jamacardio.2016.0073

This study identifies resuscitation practices associated with higher rates of in-hospital cardiac arrest survival.

von Willebrand Factor Abnormalities and Heyde Syndrome in Dysfunctional Heart Valve Prostheses

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):198-204. doi:10.1001/jamacardio.2016.0075

This cohort study determines whether dysfunctional valve prostheses are associated with von Willebrand factor abnormalities, identifies their severity relative to other conditions, and describes associated bleeding and the occurrence of gastrointestinal angiodysplasia.

Brief Report

Discordance Between Appropriate Use Criteria for Nuclear Myocardial Perfusion Imaging From Different Specialty Societies: A Potential Concern for Health Policy

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):207-210. doi:10.1001/jamacardio.2016.0030

This study at an academically affiliated Veterans Affairs medical center measures discordance between the American College of Cardiology Foundation Appropriate Use Criteria and the American College of Radiology Appropriateness Criteria for gauging the usefulness of nuclear myocardial perfusion imaging.

Research Letter

Effect of the Presence and Type of Angina on Cardiovascular Events in Patients Without Known Coronary Artery Disease Referred for Elective Coronary Angiography

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):232-234. doi:10.1001/jamacardio.2016.0076

This study describes the characteristics of patients referred for typical, atypical, or no angina and examines the associations between angina type, pre鈥揷ardiac catheterization stress test results, and burden of coronary atherosclerosis identified on coronary angiography.

Recovery of Cardiac Function in Cardiomyopathy Caused by Titin Truncation

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):234-235. doi:10.1001/jamacardio.2016.0208

This study examines whether cardiac function recovery is possible in dilated cardiomyopathy caused by a genetic mutation.

Viewpoint

The US Food and Drug Administration 515 Program Initiative: Addressing the Evidence Gap for Widely Used, High-Risk Cardiovascular Devices?

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):117-118. doi:10.1001/jamacardio.2016.0002

This Viewpoint discusses the 515 Program Initiative and steps the US Food and Drug Administration has taken to modernize device regulation.

The US Food and Drug Administration Premarket Approval Process and the 515 Program Initiative: View From a Panel Chair

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):119-120. doi:10.1001/jamacardio.2016.0007

This Viewpoint discusses the premarket approval process and the 515 Program Initiative.

Editorial

Using Data to Guide Anticoagulation in Patients With Atrial Fibrillation: Does the Analysis Fit the Question?

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):121-122. doi:10.1001/jamacardio.2016.0198

The Safety of Dipeptidyl Peptidase 4 Inhibitors and the Risk for Heart Failure

Abstract Full Text
free access has audio
JAMA Cardiol. 2016;1(2):123-125. doi:10.1001/jamacardio.2016.0184
Invited Commentary

The Enigma of Glucose and Lipid Metabolism

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):145-146. doi:10.1001/jamacardio.2016.0183

Valvular Heart Disease and Acquired Type 2A von Willebrand Syndrome: The 鈥淗emostatic鈥 Waring Blender Syndrome

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):205-206. doi:10.1001/jamacardio.2016.0182

Widespread Implementation of Appropriate Use Criteria for Cardiac Imaging鈥擶hich Are 鈥淎ppropriate鈥?

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):211-212. doi:10.1001/jamacardio.2016.0052
Special Communication

I Carry Your Heart

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):213-215. doi:10.1001/jamacardio.2015.0353

This Special Communication discusses the balance between the metaphorical heart and the real heart.

Review

Same-Day Discharge After Percutaneous Coronary Intervention: Current Perspectives and Strategies for Implementation

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):216-223. doi:10.1001/jamacardio.2016.0148

This narrative review summarizes the outcomes of same-day discharge percutaneous coronary intervention and describes a framework for the development of a same-day discharge program.

From the 糖心vlog

Appropriateness of Percutaneous Coronary Intervention: Are We Acting Appropriately?

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):224-225. doi:10.1001/jamacardio.2016.0534

This clinical review examines a recently published JAMA article on Appropriate Use Criteria for percutaneous intervention and discusses the medical community鈥檚 responsibility in using appropriate care.

JAMA Cardiology Clinical Challenge

Diffusely Elevated ST Segments on Electrocardiography

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):229-230. doi:10.1001/jamacardio.2015.0338

An elderly man presents to the emergency department with a 4-day history of fever and chest tingling and electrocardiographic findings significant for diffuse ST-segment elevation. What is your diagnosis?

JAMA Cardiology Clinical Guidelines Synopsis

Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):226-227. doi:10.1001/jamacardio.2016.0178

This Clinical Guidelines Synopsis describes the 2015 update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction.

JAMA Cardiology Patient Page

Wearable Fitness Trackers and Heart Disease

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):239. doi:10.1001/jamacardio.2016.0354
JAMA Cardiology Masthead

JAMA Cardiology

Abstract Full Text
free access
JAMA Cardiol. 2016;1(2):116. doi:10.1001/jamacardio.2015.0009
×